FDA Approves First-Ever Treatment for Acquired Hypothalamic Obesity – IMCIVREE Now Available
Rhythm Pharmaceuticals receives FDA approval for IMCIVREE (setmelanotide) — the first and only treatment for acquired hypothalamic obesity.
NOTRELOAD AI
From Moon Touchdown to Record Revenue: Firefly's Breakout 2025 and Bold 2026 Outlook
Firefly Aerospace (FLY) reports record $159.9M revenue in 2025, up 163%, historic Blue Ghost moon landing, narrower losses, and $420M–$450M 2026 guidance.
XPENG Scores First-Ever Quarterly Profit — But Weak China Demand Delivers Q1 Warning
XPENG achieved its first-ever quarterly net profit of RMB 383 million in Q4 2025 with record margins. Strong full-year growth is overshadowed by disappointing Q1 2026 guidance amid weak China EV demand.
Super Micro Co-Founder Charged in $2.5 Billion AI Server Smuggling Scheme to China
US indicts Super Micro co-founder Wally Liaw for illegally diverting $2.5B Nvidia AI servers to China via Southeast Asia, evading export controls. SMCI shares plunge.
Corcept Director Drops $3.35 Million on 100,000 Shares – Strong Insider Buy Signal
Corcept Therapeutics director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys.
FedEx Raises Full-Year Profit Outlook After Strong Q3 Results, Freight Spin-Off On Track
FedEx (FDX) raised its full-year fiscal 2026 adjusted EPS guidance to $19.30–$20.10 and revenue growth forecast to 6.0%-6.5% after strong Q3 results. Adjusted earnings hit $5.25 per share, beating estimates.